Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • SB-913

    - PMLiVE

    Regenxbio’s investigational gene therapy shows promise in Hunter syndrome

    The rare genetic disease is estimated to affect one in every 100,000 to 170,000 births

    regeneron headquarters

    Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration

    The companies will develop CRISPR-based therapies for neurological and muscular diseases

    - PMLiVE

    Moderna and Life Edit partner to accelerate gene editing therapies

    The companies will jointly develop in vivo mRNA therapies for hard-to-treat diseases

    - PMLiVE

    New T-cell study demonstrates ‘powerful’ potential for tailored cancer medicine

    The results were published in a peer-reviewed paper in Nature

    Disrupting Cell Engineering with Non-Viral Modalities

    Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing...

    Impetus Digital

    - PMLiVE

    Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline

    Company was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology

    Gene Editing and Precision Medicine: The Future of Healthcare?

    Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,...

    Impetus Digital

    - PMLiVE

    Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

    Gains rights to tau-targeting drug ST-501 as part of broader alliance

    - PMLiVE

    Sangamo steps up BioMarin chase with haemophilia gene therapy data

    Updated results presented at ASH 2019

    - PMLiVE

    Vertex reveals promising data from first CRISPR-treated patients

    Investigational gene therapy has potentially curative effect

    - PMLiVE

    New results back Sangamo, UniQure haemophilia gene therapies

    Encouraging results for firms in four-way race

    - PMLiVE

    Vertex eyes Duchenne market with Exonics, CRISPR deals

    Biotech has gene-editing expertise

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links